Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Tumors Harboring NTRK Fusion 1

Interventions

larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Tumors Harboring NTRK Fusion × larotrectinib × Clear all
NCT03025360 2019-12-19

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Bayer

Approved for marketing

Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡